Abstract
Background and objective: Systemic autoimmune diseases, viral infections (COVID-19) and obesity/metabolic syndrome (MS) are all characterized by a chronic inflammatory state with some putative shared physiopathological features. Biological age and HRQoL approaches have been applied as human health and aging indices. The objective of the METAINFLAMATION study was to analyze the differences and/or similarities between subjects with systemic lupus erythematosus (SLE), long-COVID and obesity/metabolic syndrome, which are all recognized inflammatory conditions, and to compare metabolic age and HRQoL depending on weight status in those patients. Methods: A total of 232 participants (≥18 years) were recruited whose anthropometric data were collected (height, weight, bioelectrical impedance analysis, waist circumference, hip circumference and blood pressure). The patients answered different questionnaires related to socio-demographic data, metabolic history, lifestyle (physical activity, sleep habits and nutrition) and HRQoL. Metabolic age and HRQoL (SF-12) were assessed with validated tools. Differences and interactions among the three types of diseases and body mass index (BMI) as stratified by p50 were studied using a 3 × 2 (diseases × adiposity) factorial ANOVA design and with appropriate post hoc contrasts. Results: The analyses revealed significant differences in biological age (p < 0.001) between each disease and BMI (high vs. low). Interestingly, the type of disease and BMI showed an interaction concerning biological age (p < 0.05). Regarding HRQoL, significant differences (p < 0.01) were found between each pro-inflammatory condition and between both BMI groups for the PCS (Physical Component Summary), while only the MCS (Mental Component Summary) showed statistical differences among diseases (p < 0.001) but not for BMI (p = 0.42). Additionally, the PCS evidenced a statistically significant modification of the effect (p < 0.01) depending on the type of disease as conditioned by the BMI (high vs. low) but not for the MCS (p = 0.13). Discussion. Featuring precision indices such as biological age and HRQoL in patients with SLE, long-COVID, and obesity/metabolic syndrome and interactions with ponderal status enables better monitoring of these inflammatory diseases. Metabolic individualization and the early prevention of associated complications can be achieved by using validated biomarkers and scores, seeking the personalization of therapeutic management with clinical precision.
Author Contributions
Conceptualization, J.A.M. and A.C.-S.; methodology, L.C.-S., M.M.-U. and A.H.-G.; software, V.d.l.O.; validation, R.C. and A.C.-S.; formal analysis, A.C.-S. and L.C.-S.; investigation, L.C.-S.; resources, A.H.-G. and M.M.-U.; data curation, A.C.-S.; writing—original draft preparation, A.C.-S. and L.C.-S.; writing—review and editing, J.A.M. and R.C.; visualization, J.A.M.; supervision, J.A.M.; project administration, A.C.-S. and R.C.; funding acquisition, J.A.M. All authors have read and agreed to the published version of the manuscript.
Funding
This research was funded by Community of Madrid, Spain (SINERGICOS 2020 projects) grant number [METAINFLAMACION Y2020/BIO-6600].
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Research Ethics Committee of the Puerta de Hierro Majadahonda University Hospital (Madrid, Spain) with file number (PI 164-21).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
The data presented in this study are available on request from the corresponding author. The data are not publicly available due to the clinical trial is not finished.
Conflicts of Interest
The authors declare no conflict of interest.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).